Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 2
1975 1
1976 2
1978 1
1979 1
1981 2
1982 6
1983 9
1984 6
1985 9
1986 8
1987 3
1988 8
1989 6
1990 9
1991 11
1992 4
1993 2
1994 3
1995 7
1996 5
1997 6
1998 4
1999 11
2000 16
2001 21
2002 3
2003 5
2004 4
2005 5
2006 5
2007 3
2008 9
2009 9
2010 7
2011 8
2012 5
2013 10
2014 9
2015 14
2016 8
2017 8
2018 9
2019 7
2020 11
2021 9
2022 8
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

316 results

Results by year

Filters applied: . Clear all
Page 1
Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations.
Freedman MS, Devonshire V, Duquette P, Giacomini PS, Giuliani F, Levin MC, Montalban X, Morrow SA, Oh J, Rotstein D, Yeh EA; Canadian MS Working Group. Freedman MS, et al. Among authors: giacomini ps. Can J Neurol Sci. 2020 Jul;47(4):437-455. doi: 10.1017/cjn.2020.66. Epub 2020 Apr 6. Can J Neurol Sci. 2020. PMID: 32654681 Review.
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Hauser SL, Cross AH, Winthrop K, Wiendl H, Nicholas J, Meuth SG, Giacomini PS, Saccà F, Mancione L, Zielman R, Bagger M, Das Gupta A, Häring DA, Jehl V, Kieseier BC, Pingili R, Stoneman D, Su W, Willi R, Kappos L. Hauser SL, et al. Among authors: giacomini ps. Mult Scler. 2022 Sep;28(10):1576-1590. doi: 10.1177/13524585221079731. Epub 2022 Mar 1. Mult Scler. 2022. PMID: 35229668 Free PMC article. Clinical Trial.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
Unknown primary tumors.
Natoli C, Ramazzotti V, Nappi O, Giacomini P, Palmeri S, Salvatore M, Landriscina M, Zilli M, Natali PG, Tinari N, Iacobelli S. Natoli C, et al. Among authors: giacomini p. Biochim Biophys Acta. 2011 Aug;1816(1):13-24. doi: 10.1016/j.bbcan.2011.02.002. Epub 2011 Mar 1. Biochim Biophys Acta. 2011. PMID: 21371531 Review.
Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach.
Ricciardi E, Giordani E, Ziccheddu G, Falcone I, Giacomini P, Fanciulli M, Russillo M, Cerro M, Ciliberto G, Morrone A, Guerrisi A, Valenti F. Ricciardi E, et al. Among authors: giacomini p. Int J Mol Sci. 2023 Feb 16;24(4):4014. doi: 10.3390/ijms24044014. Int J Mol Sci. 2023. PMID: 36835424 Free PMC article. Review.
Antigen-specific therapies in multiple sclerosis.
Giacomini PS, Bar-Or A. Giacomini PS, et al. Expert Opin Emerg Drugs. 2009 Sep;14(3):551-60. doi: 10.1517/14728210903203790. Expert Opin Emerg Drugs. 2009. PMID: 19708820 Review.
Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer.
Ciliberto G, Canfora M, Terrenato I, Agnoletto C, Agustoni F, Amoroso L, Baldassarre G, Curigliano G, Delmonte A, De Luca A, Fiorentino M, Gregorc V, Ibrahim T, Lazzari C, Mastronuzzi A, Pronzato P, Santoro A, Scambia G, Tommasi S, Vingiani A, Giacomini P, De Maria R. Ciliberto G, et al. Among authors: giacomini p. J Exp Clin Cancer Res. 2022 Oct 17;41(1):305. doi: 10.1186/s13046-022-02512-0. J Exp Clin Cancer Res. 2022. PMID: 36245005 Free PMC article.
Diagnosis and management of secondary-progressive multiple sclerosis: time for change.
Oh J, Alikhani K, Bruno T, Devonshire V, Giacomini PS, Giuliani F, Nakhaipour HR, Schecter R, Larochelle C. Oh J, et al. Among authors: giacomini ps. Neurodegener Dis Manag. 2019 Dec;9(6):301-317. doi: 10.2217/nmt-2019-0024. Epub 2019 Nov 26. Neurodegener Dis Manag. 2019. PMID: 31769344 Free article. Review.
316 results